Response to crizotinib after entrectinib resistance in ROS1-rearranged, MET-amplified lung adenocarcinoma Journal Article

  

Authors:	Vaz, V. R.; Gandhi, M. M.; Ricciuti, B.; Alessi, J. V.; Elkrief, A.; Ladanyi, M.; Vanderbilt, C.; Pecci, F.; Aldea, M.; Barrichello, A.; Saini, A.; Sholl, L.; Sands, J. M.; Awad, M. M.
Article Title:	Response to crizotinib after entrectinib resistance in ROS1-rearranged, MET-amplified lung adenocarcinoma
Abstract:	Crizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure. © 2024 by American Society of Clinical Oncology.
Journal Title:	JCO Precision Oncology
Volume:	8
ISSN:	2473-4284
Publisher:	American Society of Clinical Oncology
Date Published:	2024-10-01
Start Page:	e2400394
Language:	English
DOI:	10.1200/po-24-00394
PUBMED:	39374479
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85206923264&doi=10.1200%2fPO-24-00394&partnerID=40&md5=0684d2db71ad461abf40f172064b0a69
Notes:	Article -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/219869